List of Excipients in API dextromethorphan hydrobromide, bupropion hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing dextromethorphan hydrobromide, bupropion hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Axsome Therapeutics Inc | AUVELITY | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 | CARBOMER HOMOPOLYMER TYPE | 2034-11-05 |
| Axsome Therapeutics Inc | AUVELITY | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 | CELLULOSE, MICROCRYSTALLINE | 2034-11-05 |
| Axsome Therapeutics Inc | AUVELITY | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 | CROSPOVIDONE | 2034-11-05 |
| Axsome Therapeutics Inc | AUVELITY | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 | CYSTEINE HYDROCHLORIDE | 2034-11-05 |
| Axsome Therapeutics Inc | AUVELITY | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 | FERRIC OXIDE RED | 2034-11-05 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for dextromethorphan hydrobromide, bupropion hydrochloride
Excipient focus: CARBOMER HOMOPOLYMER TYPE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing CARBOMER HOMOPOLYMER TYPE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing CARBOMER HOMOPOLYMER TYPE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CYSTEINE HYDROCHLORIDE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing CYSTEINE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing CYSTEINE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL MONOCAPRYLATE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing GLYCERYL MONOCAPRYLATE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing GLYCERYL MONOCAPRYLATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STEARIC ACID
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing STEARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing STEARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
dextromethorphan hydrobromide, bupropion hydrochloride drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Axsome Therapeutics Inc | dextromethorphan hydrobromide, bupropion hydrochloride | 81968-045 |
| >Company | >Ingredient | >NDC |
dextromethorphan hydrobromide, bupropion hydrochloride drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links